Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A method of ~~treating~~ reducing a lesion of cerebral tissue induced by cerebral ischemia, wherein the cerebral ischemia occurs as a result of apoplexy, said method comprising the step of administering to a subject in need thereof a medicament comprising a neuroprotective amount of an active ingredient comprising a hydrogenation product of *Boswellia serrata* obtained through the catalytic hydrogenation of ethanol extracts of frankincense (*Boswellia serrata*).

2. (Canceled) ~~The method according to claim 1, wherein the cerebral ischemia occurs as a result of apoplexy.~~

3. (Previously Presented) The method according to claim 1, wherein the active ingredient comprises frankincense or a boswellic acid-containing vegetable extract.

4. (Previously Presented) The method according to claim 1, wherein the frankincense extract is selected from the group consisting of a keto-boswellic acid, 3-O-acetyl-11-keto-ß-boswellic acid, 11-keto-ß-boswellic acid, a physiologically acceptable salt of a keto-boswellic acid, a derivative of a keto-boswellic acid, a salt of a keto-boswellic acid derivative, and a keto-boswellic acid-containing vegetable extract.

5. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises a tirucallic acid, another triterpene or a salt or derivative thereof or a vegetable extract containing a tirucallic acid, another triterpene or a salt or derivative thereof.

6. (Previously Presented) The method according to claim 1, wherein the frankincense extract comprises an extract from a *Boswellia serrata* resin.

7. (Currently Amended) A method of reducing a lesion of cerebral tissue induced by ~~treating~~ a cranial/brain trauma or, a short-term cerebral ischemia resulting from apoplexy or cardiac infarction, said method ~~and/or Alzheimer's disease~~ comprising the step of administering to a subject in need thereof a medicament comprising a neuroprotective amount of an active ingredient selected from the group consisting of: a hydrogenation product of a frankincense extract and a physiologically acceptable salt of said hydrogenation product.

8. (Canceled) ~~The method according to claim 7, wherein the medicament is used for treating Alzheimer's disease~~.

9. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenation product of a boswellic acid-containing vegetable extract.

10. (Previously Presented) The method according to claim 7, wherein the active ingredient comprises a hydrogenated product of a frankincense extract obtained from a *Boswellia serrata* resin.

11. (Previously Presented) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a hydrogenation product of boswellic acid and a physiologically acceptable salt of said hydrogenation product .

12. (Canceled).

13. (Canceled)

14. (Canceled)

15. (Previously Presented) The method according to claim 7, wherein the active ingredient is selected from the group consisting of a hydrogenation product of tirucallic acid and a physiologically acceptable salt of said hydrogenation product.

16. (Previously Presented) The method according to claim 1, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

17. (Previously Presented) The method according to claim 1, wherein the medicament comprises a tablet or solution.

18. (Previously Presented) The method according to claim 7, wherein the medicament is formulated for intraperitoneal, oral, buccal, rectal, intramuscular, topical, subcutaneous, intraarticular, intravenous, intrathecal or intracranial administration.

19. (Previously Presented) The method according to claim 7, wherein the medicament comprises a tablet or solution.